Neuropeptide receptor ligands as drugs for psychiatric diseases: the end of the beginning? (Q34275762)

1 August 2017

title

Neuropeptide receptor ligands as drugs for psychiatric diseases: the end of the beginning? (English)

1 reference

1 August 2017

2

Florian Holsboer

0 references

author name string

Guy Griebel

series ordinal

1

1 reference

1 August 2017

publication date

18 May 2012

1 reference

Nature Reviews Drug Discovery

1 August 2017

published in

1 reference

1 August 2017

volume

11

1 reference

1 August 2017

issue

6

1 reference

1 August 2017

page(s)

462-478

1 reference

Distinct mechanism for antidepressant activity by blockade of central substance P receptors

1 August 2017

cites work

1 reference

Neuropeptides in psychiatric diseases: an overview with a particular focus on depression and anxiety disorders.

21 January 2018

1 reference

Is there a future for neuropeptide receptor ligands in the treatment of anxiety disorders?

21 January 2018

1 reference

Cholecystokinin antagonists: pharmacological and therapeutic potential

21 January 2018

1 reference

Species differences in tachykinin receptor distribution: further evidence that the substance P (NK1) receptor predominates in human brain

21 January 2018

1 reference

A 25 year adventure in the field of tachykinins

21 January 2018

1 reference

The gerbil elevated plus-maze II: anxiolytic-like effects of selective neurokinin NK1 receptor antagonists

21 January 2018

1 reference

The gerbil elevated plus-maze I: behavioral characterization and pharmacological validation

21 January 2018

1 reference

Activation of dopaminergic and cholinergic neurotransmission by tachykinin NK3 receptor stimulation: an in vivo microdialysis approach in guinea pig.

21 January 2018

1 reference

Substance P receptor antagonists in psychiatry: rationale for development and therapeutic potential

21 January 2018

1 reference

The role of substance P in stress and anxiety responses

21 January 2018

1 reference

Effect of neurokinin-1 receptor antagonists on serotoninergic, noradrenergic and hippocampal neurons: comparison with antidepressant drugs

21 January 2018

1 reference

Demonstration of the efficacy and safety of a novel substance P (NK1) receptor antagonist in major depression

21 January 2018

1 reference

Results from 2 randomized, double-blind, placebo-controlled studies of the novel NK1 receptor antagonist casopitant in patients with major depressive disorder

21 January 2018

1 reference

Lack of efficacy of the substance p (neurokinin1 receptor) antagonist aprepitant in the treatment of major depressive disorder

21 January 2018

1 reference

Development of the 2nd generation neurokinin-1 receptor antagonist LY686017 for social anxiety disorder

21 January 2018

1 reference

A selective neurokinin-1 receptor antagonist in chronic PTSD: a randomized, double-blind, placebo-controlled, proof-of-concept trial

21 January 2018

1 reference

Discovery of the antidepressant and anti-emetic efficacy of substance P receptor (NK1) antagonists

21 January 2018

1 reference

Tachykinin receptors as therapeutic targets in stress-related disorders.

21 January 2018

1 reference

Short-term NK1 receptor antagonism and emotional processing in healthy volunteers.

21 January 2018

1 reference

NK1 receptor antagonism and emotional processing in healthy volunteers.

21 January 2018

1 reference

NK1 receptor antagonism and the neural processing of emotional information in healthy volunteers.

21 January 2018

1 reference

A potent and selective non-peptide antagonist of the neurokinin a (NK2) receptor

21 January 2018

1 reference

Additional evidence for anxiolytic- and antidepressant-like activities of saredutant (SR48968), an antagonist at the neurokinin-2 receptor in various rodent-models

21 January 2018

1 reference

Saredutant, an NK2 receptor antagonist, has both antidepressant-like effects and synergizes with desipramine in an animal model of depression

21 January 2018

1 reference

Effects of SR48968, a selective non-peptide NK2 receptor antagonist on emotional processes in rodents

21 January 2018

1 reference

Therapeutic utility of NK3 receptor antagonists for the treatment of schizophrenia

21 January 2018

1 reference

Tachykinin neurokinin 3 receptor antagonists: a patent review (2005 - 2010).

21 January 2018

1 reference

Is there still a future for neurokinin 3 receptor antagonists as potential drugs for the treatment of psychiatric diseases?

21 January 2018

1 reference

Opinion: NK3 receptor antagonists: the next generation of antipsychotics?

21 January 2018

1 reference

Placebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorder

21 January 2018

1 reference

Psychomotor and cognitive effects of a single oral dose of talnetant (SB223412) in healthy volunteers compared with placebo or haloperidol.

21 January 2018

1 reference

Characterization of a 41-Residue Ovine Hypothalamic Peptide That Stimulates Secretion of Corticotropin and β-Endorphin

21 January 2018

1 reference

International Union of Pharmacology. XXXVI. Current status of the nomenclature for receptors for corticotropin-releasing factor and their ligands

21 January 2018

1 reference

Stress and central Urocortin increase anxiety-like behavior in the social interaction test via the CRF1 receptor

21 January 2018

1 reference

Corticotropin-releasing factor receptors: physiology, pharmacology, biochemistry and role in central nervous system and immune disorders

21 January 2018

1 reference

Corticotropin-releasing factor receptors 1 and 2 in anxiety and depression

21 January 2018

1 reference

Corticotropin releasing factor (CRF) receptor signaling in the central nervous system: new molecular targets

21 January 2018

1 reference

Corticotropin-releasing hormone activates ERK1/2 MAPK in specific brain areas.

21 January 2018

1 reference

Effects of the high-affinity corticotropin-releasing hormone receptor 1 antagonist R121919 in major depression: the first 20 patients treated

21 January 2018

1 reference

Animal models of neuropsychiatric disorders

21 January 2018

1 reference

Causal relationship between stressful life events and the onset of major depression

21 January 2018

1 reference

21 January 2018

Stress and depression

1 reference

Conditional corticotropin-releasing hormone overexpression in the mouse forebrain enhances rapid eye movement sleep

21 January 2018

1 reference

In quest of identifying vulnerability markers for psychiatric disorders by all-night polysomnography.

21 January 2018

1 reference

Treatment with the CRH1-receptor-antagonist R121919 improves sleep-EEG in patients with depression

21 January 2018

1 reference

Stress hormone regulation: biological role and translation into therapy

21 January 2018

1 reference

Combined effects of exonic polymorphisms in CRHR1 and AVPR1B genes in a case/control study for panic disorder

21 January 2018

1 reference

The involvement of the vasopressin system in stress-related disorders

21 January 2018

1 reference

Corticotropin-releasing factor, vasopressin and receptor systems in depression and anxiety

21 January 2018

1 reference

Association of a corticotropin-releasing hormone receptor 1 haplotype and antidepressant treatment response in Mexican-Americans

21 January 2018

1 reference

Association of polymorphisms in genes regulating the corticotropin-releasing factor system with antidepressant treatment response.

21 January 2018

1 reference

Sequence variations of ABCB1, SLC6A2, SLC6A3, SLC6A4, CREB1, CRHR1 and NTRK2: association with major depression and antidepressant response in Mexican-Americans

21 January 2018

1 reference

Influence of child abuse on adult depression: moderation by the corticotropin-releasing hormone receptor gene

21 January 2018

1 reference

Protective effect of CRHR1 gene variants on the development of adult depression following childhood maltreatment: replication and extension

21 January 2018

1 reference

Childhood maltreatment, the corticotropin-releasing hormone receptor gene and adult depression in the general population.

21 January 2018

1 reference

Interaction of childhood maltreatment with the corticotropin-releasing hormone receptor gene: effects on hypothalamic-pituitary-adrenal axis reactivity

21 January 2018

1 reference

Dynamic DNA methylation programs persistent adverse effects of early-life stress

21 January 2018

1 reference

Resilience to social stress coincides with functional DNA methylation of the Crf gene in adult mice.

21 January 2018

1 reference

Therapeutic plasma concentrations of antidepressants and antipsychotics: lessons from PET imaging.

21 January 2018

1 reference

PET Imaging of CRF1 with [11C]R121920 and [11C]DMP696: is the target of sufficient density?

21 January 2018

1 reference

Polymorphisms in the drug transporter gene ABCB1 predict antidepressant treatment response in depression

21 January 2018

1 reference

High-affinity CRF1 receptor antagonist NBI-34041: preclinical and clinical data suggest safety and efficacy in attenuating elevated stress response

21 January 2018

1 reference

Vasopressinergic control of pituitary adrenocorticotropin secretion comes of age.

21 January 2018

1 reference

Regulation of pituitary ACTH secretion during chronic stress

21 January 2018

1 reference

Behavioral consequences of intracerebral vasopressin and oxytocin: focus on learning and memory

21 January 2018

1 reference

The origin of the vasopressinergic and oxytocinergic innervation of the rat brain with special reference to the lateral septum.

21 January 2018

1 reference

Vasopressin-immunoreactive cell bodies in the bed nucleus of the stria terminalis of the rat

21 January 2018

1 reference

Extrapituitary expression of the rat V1b vasopressin receptor gene

21 January 2018

1 reference

Localization of vasopressin (V1a) receptor binding and mRNA in the rhesus monkey brain

21 January 2018

1 reference

Molecular cloning and expression of a rat V1a arginine vasopressin receptor

21 January 2018

1 reference

Binding of the non-peptide vasopressin V1a receptor antagonist SR-49059 in the rat brain: an in vitro and in vivo autoradiographic study

21 January 2018

1 reference

Evidence that the lateral septum is involved in the antidepressant-like effects of the vasopressin V1b receptor antagonist, SSR149415.

21 January 2018

1 reference

Vasopressinergic regulation of the hypothalamic-pituitary-adrenal axis: implications for stress adaptation

21 January 2018

1 reference

Dose response of arginine vasopressin to the CCK-B agonist pentagastrin

21 January 2018

1 reference

Increased number of vasopressin- and oxytocin-expressing neurons in the paraventricular nucleus of the hypothalamus in depression.

21 January 2018

1 reference

Alterations in arginine vasopressin neurons in the suprachiasmatic nucleus in depression

21 January 2018

1 reference

Plasma levels of arginine vasopressin elevated in patients with major depression.

21 January 2018

1 reference

Abnormalities in the regulation of vasopressin and corticotropin releasing factor secretion in obsessive-compulsive disorder

21 January 2018

1 reference

Anxiolytic- and antidepressant-like effects of the non-peptide vasopressin V1b receptor antagonist, SSR149415, suggest an innovative approach for the treatment of stress-related disorders.

21 January 2018

1 reference

Corticotropin releasing activity of the new CRF is potentiated several times by vasopressin

21 January 2018

1 reference

Combined administration of human corticotropin-releasing factor and lysine vasopressin induces cortisol escape from dexamethasone suppression in healthy subjects

21 January 2018

1 reference

Stress and the brain: from adaptation to disease

21 January 2018

1 reference

Restriction of HIV-1 replication in monocytes is abolished by Vpx of SIVsmmPBj

21 January 2018

1 reference

Clinical characteristics and treatment outcome in a representative sample of depressed inpatients - findings from the Munich Antidepressant Response Signature (MARS) project

21 January 2018

1 reference

Venlafaxine and mirtazapine treatment lowers serum concentrations of dehydroepiandrosterone-sulfate in depressed patients remitting during the course of treatment

21 January 2018

1 reference

21 January 2018

1 reference

Non-peptide vasopressin V1b receptor antagonists as potential drugs for the treatment of stress-related disorders

21 January 2018

1 reference

The vasopressin Avpr1b receptor: molecular and pharmacological studies

21 January 2018

1 reference

Characterization of a novel and selective V1B receptor antagonist

21 January 2018

1 reference

Neurotensin: role in psychiatric and neurological diseases.

21 January 2018

1 reference

Novel treatments of schizophrenia: targeting the neurotensin system

21 January 2018

1 reference

Neurotensin agonists: potential in the treatment of schizophrenia

21 January 2018

1 reference

Structure and functional expression of the cloned rat neurotensin receptor

21 January 2018

1 reference

Molecular cloning of a levocabastine-sensitive neurotensin binding site

21 January 2018

1 reference

The 100-kDa neurotensin receptor is gp95/sortilin, a non-G-protein-coupled receptor

21 January 2018

1 reference

The effects of deleting the mouse neurotensin receptor NTR1 on central and peripheral responses to neurotensin

21 January 2018

1 reference

Cellular distribution of neurotensin receptors in rat brain: immunohistochemical study using an antipeptide antibody against the cloned high affinity receptor

21 January 2018

1 reference

Localization of neuropeptide receptor mRNA in rat brain: Initial observations using probes for neurotensin and substance P receptors

21 January 2018

1 reference

Distribution of the neurotensin receptor NTS1 in the rat CNS studied using an amino-terminal directed antibody

21 January 2018

1 reference

Neurotensin analog selective for hypothermia over antinociception and exhibiting atypical neuroleptic-like properties

21 January 2018

1 reference

In vitro binding and CNS effects of novel neurotensin agonists that cross the blood-brain barrier

21 January 2018

1 reference

Trillion-dollar brain drain.

21 January 2018

1 reference

How can we realize the promise of personalized antidepressant medicines?

21 January 2018

1 reference

Considerations about the efficacy of psychopharmacological drugs

21 January 2018

1 reference

Neuropeptides: opportunities for drug discovery

21 January 2018

1 reference

21 January 2018

1 reference

Glutamatergic and dopaminergic neurons mediate anxiogenic and anxiolytic effects of CRHR1.

21 January 2018

1 reference

Quality of Life of Adolescents With Perceived Disabilities

21 January 2018

1 reference

The link between childhood trauma and depression: insights from HPA axis studies in humans.

21 January 2018

1 reference

Child sexual abuse and subsequent psychopathology: results from the National Comorbidity Survey.

21 January 2018

1 reference

The corticosteroid receptor hypothesis of depression

21 January 2018

1 reference

The combined dexamethasone/CRH test as a potential surrogate marker in depression

21 January 2018

1 reference

When not enough is too much: the role of insufficient glucocorticoid signaling in the pathophysiology of stress-related disorders

21 January 2018

1 reference

The role of corticotropin-releasing factor in the pathogenesis of major depression

21 January 2018

1 reference

Genetic variability at HPA axis in major depression and clinical response to antidepressant treatment

21 January 2018

1 reference

The rationale for corticotropin-releasing hormone receptor (CRH-R) antagonists to treat depression and anxiety

21 January 2018

1 reference

21 January 2018

1 reference

Persistent elevations of cerebrospinal fluid concentrations of corticotropin-releasing factor in adult nonhuman primates exposed to early-life stressors: implications for the pathophysiology of mood and anxiety disorders

21 January 2018

1 reference

Forebrain CRF₁ modulates early-life stress-programmed cognitive deficits

21 January 2018

1 reference

Long-term, progressive hippocampal cell loss and dysfunction induced by early-life administration of corticotropin-releasing hormone reproduce the effects of early-life stress.

21 January 2018

1 reference

Hippocampal dysfunction and cognitive impairments provoked by chronic early-life stress involve excessive activation of CRH receptors

21 January 2018

1 reference

Limbic corticotropin-releasing hormone receptor 1 mediates anxiety-related behavior and hormonal adaptation to stress.

21 January 2018

1 reference

Transient early-life forebrain corticotropin-releasing hormone elevation causes long-lasting anxiogenic and despair-like changes in mice

21 January 2018

1 reference

Characterization of the behavioral profile of the non-peptide CRF receptor antagonist CP-154,526 in anxiety models in rodents. Comparison with diazepam and buspirone

21 January 2018

1 reference

Oral administration of a corticotropin-releasing hormone receptor antagonist significantly attenuates behavioral, neuroendocrine, and autonomic responses to stress in primates

21 January 2018

1 reference

Therapeutic potential of neuropeptide Y (NPY) receptor ligands.

21 January 2018

1 reference

The orphanin FQ/nociceptin (OFQ/N) system

21 January 2018

1 reference

Melanin-concentrating hormone MCH1 receptor antagonists: a potential new approach to the treatment of depression and anxiety disorders

21 January 2018

1 reference

The melanin-concentrating hormone (MCH) system modulates behaviors associated with psychiatric disorders

21 January 2018

1 reference

Neuropeptide systems as novel therapeutic targets for depression and anxiety disorders

21 January 2018

1 reference

The galanin peptide family: receptor pharmacology, pleiotropic biological actions, and implications in health and disease

21 January 2018

1 reference

Prosocial effects of oxytocin and clinical evidence for its therapeutic potential

21 January 2018

1 reference

Neuropeptide S: a neuropeptide promoting arousal and anxiolytic-like effects

21 January 2018

1 reference

Intranasally administered neuropeptide S (NPS) exerts anxiolytic effects following internalization into NPS receptor-expressing neurons

21 January 2018

1 reference

A 6-week randomized, placebo-controlled trial of CP-316,311 (a selective CRH1 antagonist) in the treatment of major depression

21 January 2018

1 reference

Discontinued psychiatric drugs in 2008.

21 January 2018

1 reference

Multicenter, randomized, double-blind, active comparator and placebo-controlled trial of a corticotropin-releasing factor receptor-1 antagonist in generalized anxiety disorder

21 January 2018

1 reference

Cerebral blood flow changes after treatment of social phobia with the neurokinin-1 antagonist GR205171, citalopram, or placebo

21 January 2018

1 reference

Randomized, double-blind study of SR142801 (Osanetant). A novel neurokinin-3 (NK3) receptor antagonist in panic disorder with pre- and posttreatment cholecystokinin tetrapeptide (CCK-4) challenges

21 January 2018

1 reference

Developing small molecule nonpeptidergic drugs for the treatment of anxiety disorders: is the challenge still ahead?

21 January 2018

1 reference

A Potent Nonpeptide Antagonist of the Substance P (NK 1 ) Receptor

31 March 2020

1 reference

Is bigger better for depression trials?

31 March 2020

1 reference

Identification of a new series of non-peptidic NK3 receptor antagonists

31 March 2020

1 reference

Localization of novel corticotropin-releasing factor receptor (CRF2) mRNA expression to specific subcortical nuclei in rat brain: comparison with CRF1 receptor mRNA expression

31 March 2020

1 reference

Conditional CRH overexpressing mice: an animal model for stress-elicited pathologies and treatments that target the central CRH system

31 March 2020

1 reference

Association of corticotropin-releasing hormone receptor1 gene SNP and haplotype with major depression

31 March 2020

1 reference

Vasopressin cells in the medial amygdala of the rat project to the lateral septum and ventral hippocampus

31 March 2020

1 reference

Comparative distribution of vasopressin V1b and oxytocin receptor messenger ribonucleic acids in brain

31 March 2020

1 reference

Cerebrospinal fluid vasopressin--changes in depression

31 March 2020

1 reference

Desmopressin normalizes the blunted adrenocorticotropin response to corticotropin-releasing hormone in melancholic depression: evidence of enhanced vasopressinergic responsivity

31 March 2020

1 reference

Combined Dexamethasone/Corticotropin Releasing Hormone Test Predicts Treatment Response in Major Depression–A Potential Biomarker?

31 March 2020

1 reference

Highly potent neurotensin analog that causes hypothermia and antinociception

31 March 2020

1 reference

Pharmacokinetics of novel hexapeptides with neurotensin activity in rats

31 March 2020

1 reference

Stability of a novel hexapeptide, (Me)Arg-Lys-Pro-Trp-tert-Leu-Leu-OEt, with neurotensin activity, in aqueous solution and in the solid state

31 March 2020

1 reference

Effects of neurotensin receptor antagonists on the firing rate of rat ventral pallidum neurons

31 March 2020

1 reference

Selective blockade of neurokinin-2 receptors produces antidepressant-like effects associated with reduced corticotropin-releasing factor function

31 March 2020

1 reference

12 December 2020

SR 142801, the first potent non-peptide antagonist of the tachykinin NK3 receptor

1 reference

12 December 2020

Clinical characteristics of women with a history of childhood abuse: unhealed wounds

1 reference

12 December 2020

The Isolation of a New Hypotensive Peptide, Neurotensin, from Bovine Hypothalami

1 reference

12 December 2020

Novel NK(3) receptor antagonists for the treatment of schizophrenia and other CNS indications.

1 reference

12 December 2020

Contribution of life events to causation of psychiatric illness

1 reference

12 December 2020

Antidepressants and hypothalamic-pituitary-adrenocortical regulation

1 reference

12 December 2020

Neurobiology of corticotropin releasing factor (CRF) receptors and CRF-binding protein: implications for the treatment of CNS disorders

1 reference

12 December 2020

Identification and characterization of a 3',5'-cyclic adenosine monophosphate-responsive element in the human corticotropin-releasing hormone gene promoter

1 reference

12 December 2020

Receptors and antagonists for substance P and related peptides

1 reference

12 December 2020

Talnetant GlaxoSmithKline.

1 reference

12 December 2020

Evidence for a role of the supraopticohypophyseal system in regulation of adrenocorticotrophin secretion.

1 reference

12 December 2020

Widespread expression in adult rat forebrain of mRNA encoding high-affinity neurotensin receptor

1 reference

12 December 2020

Neurotensin, a multi-action peptide hormone

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRD3702

1 reference

release_g75kbzpe6reolfytnmbmva7pne

1 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/g75kbzpe6reolfytnmbmva7pne

24 November 2022

mapped directly with Wikidata item

1 reference